• Lyphe group

  Participated · Series A · May 2022

  Lyphe is a London-based medical cannabis ecosystem offering patient care, medical treatments and direct-to-patient digital services. It operates a digital-first patient-access platform that provides clinics, dispensing, import infrastructure and educational services to patients, doctors and the industry. The company supports telehealth, dispensing and technology services via a team of more than 100 employees. Lyphe intends to use the new funding to expand into multiple markets across Europe. The £5m Series A follows a strong 2021 for Lyphe Group, when revenues increased by more than 250% year-over-year. CEO Jonathan Nadler framed the business as a digital-first patient-access ecosystem serving patients, clinicians and the wider industry.

No current team members are available.